ErVimmune
French tech company | Builders Republic
Formerly ERVACCINE
About
Biotech developing off-the-shelf therapeutic cancer vaccines that target unusual tumor markers produced by ancient virus DNA embedded in the human genome — pairing an AI-driven discovery platform with a lead vaccine candidate, aimed at triple-negative breast and ovarian cancers.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2019
- City
- LYON
- Region
- Auvergne-Rhône-Alpes
- Tracked rounds
- 2
- Amount raised
- 19 M€ raised since 2020
Funding rounds
- Series A — 2026
- Seed — 2022
Investors
- Seventure Partners
- SPRIM Global Investments
Notes
Renommée (ex-ERvaccine Technologies)